MFN News Items – Page 13

Commercialization start in Italy after successful pilot

iZafe Group (publ.) hereby announces that the partner Remedio S.R.L is ready with its pilot of Dosell which will be included in its concept Sempli Farma. An initial order for 50 Dosell will be sent to Italy this week.

“We have for a long time tested and evaluated Dosell together with the Sempli Farma concept, which enables a safer and simpler medication at home together with the local pharmacy. In connection with all parts now being in place, I have brought in a commercial team of 3 people who will actively work with sales to the 20,000 pharmacies in Italy, and also find partners that will offer Sempli Farma including Dosell in its portfolios” says Alessando Iadecola, CEO Remedio S.R.L.

"We are very pleased with this news for several reasons. We think that the concept is very exciting where you are not limited by the sachet market as the sachets are included as part of the service and we see great potential for similar concepts in other countries. And that the Italian market has a huge potential where there are over 8.8 million people who are over 65 and take more than 5 medicines a day.
With EUR 20 billion in annual costs linked to incorrect medication in Italy, we hope that the Sempli Farma concept can contribute to safer care where lives are saved and injuries avoided, as well as saving large costs for society.” says Anders Segerström, CEO of iZafe Group AB.

About Sempli Farma by Remedio S.R.L
The Italian healthcare company Remedio has built a network of strategically selected partners in Italy to find a combination of different aids in drug management and distribution channels that enable the elderly to stay at home longer. Unlike in Sweden, the possibility of receiving medicine on a dose roll has not existed in Italy; this has inspired Remedio to launch the concept of sachets and develop the complete solution Sempli Farma.

Sempli Farma is a service that connects pharmacists with the patient and their relatives via a pharmacy through a closed system for drug dispensing. The care concept aims to reduce care costs and streamline the Italian healthcare system. Dosell becomes the ultimate end component by delivering the dose bags while at the same time the compliance of the medication can be checked and statistics obtained.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

About Us

iZafe Group is a Swedish Life-Science company that develops and markets medical and digital security solutions to create safer drug handling at home. The company’s digital medication dispenser Dosell reduces the risk of incorrect medication, increases security for family and relatives and relieves public care personnel. The products form a holistic concept that facilitates patient medication and gives those who are treated at home better conditions for a happy and safe life. Customers today consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe Group sells primarily through well-established partners who already have long and deep customer relationships with the priority customer groups. The head office is located in Stockholm.

The company is listed on the NASDAQ First North Premier Growth Market. FNCA Sweden AB is the company's Certified Adviser. Phone: +46 (0) 8 528 00 399. E-mail: . Further information is available at www.izafe.se/investor-relations/.

Commercialization start in Italy after successful pilot

15 Dosell are implemented in a new municipality.

iZafe Group (publ.) hereby announces that the partner Zafe Care Systems AB has now begun implementation of 15 Dosell in a municipality in southern Sweden.

The municipality, which has about 14,800 inhabitants who are 65 years and older, initially starts with 15 Dosell with an ambition to increase the number gradually.

About Zafe
Zafe Care Systems AB, which was acquired by the AddLife Group, is part of Home Care, similar to Norwegian Hepro, and is one of the leading companies in welfare technology on the Swedish market. Their main customers are the state, municipalities and aid centers. Today, they work with more than 200 municipalities and are suitable thanks to their market-leading technology in all types of care homes.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

About Us

15 Dosell are implemented in a new municipality.

5 Dosell are implemented in a new municipality.

iZafe Group (publ.) hereby announces that the partner Hepro AS has now starting implementation of 5 Dosell in a municipality in the northern region of Norway.

The municipality, which has about 640 inhabitants who are 65 years and older, initially starts with 5 Dosell with an ambition to increase the number gradually.

About Hepro
HEPRO AS is a modern and future-oriented competence company that develops, produces and sells aids and welfare technology of high quality and clean design. The company was founded in 1987 and has extensive experience in developing products and solutions that will make everyday life easier for their customers. Their vision is to give their customers the opportunity to manage themselves, participate actively in their own everyday lives and stay longer at home. Hepro is owned by the Stockholm-based listed AddLife Group. AddLife has approx. 70 st. independent subsidiaries and over 1800 employees.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

About Us

5 Dosell are implemented in a new municipality.

iZafe Group (publ.) hereby announces that the partner Zafe Care Systems AB has now begun implementation of 5 Dosell in a municipality in southern Sweden.

The municipality, which has about 4,350 inhabitants who are 65 years and older, initially starts with 5 Dosell with an ambition to increase the number gradually.

About Zafe
Zafe Care Systems AB, which was acquired by the AddLife Group, is part of Home Care, similar to Norwegian Hepro, and is one of the leading companies in welfare technology on the Swedish market. Their main customers are the state, municipalities and aid centers. Today, they work with more than 200 municipalities and are suitable thanks to their market-leading technology in all types of care homes.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

About Us

5 Dosell are implemented in a new municipality.

10 Dosell are implemented in a new municipality.

iZafe Group (publ.) hereby announces that the partner Zafe Care Systems AB has now begun implementation of 10 Dosell in a municipality in southern Sweden.

The municipality, which has about 6,700 inhabitants who are 65 years and older, initially starts with 10 Dosell with an ambition to increase the number gradually.

About Zafe
Zafe Care Systems AB, which was acquired by the AddLife Group, is part of Home Care, similar to Norwegian Hepro, and is one of the leading companies in welfare technology on the Swedish market. Their main customers are the state, municipalities and aid centers. Today, they work with more than 200 municipalities and are suitable thanks to their market-leading technology in all types of care homes.

About Dosell
The medicinal robot Dosell is a Swedish-made digital aid for safer medication at home and for people living in nursing homes. Dosell is integrated into welfare platforms and is sold as one of several integrated digital aids via partners.
In a Swedish report, it is estimated that 3,000 Swedes die annually from drug-related injuries and that 6–16 percent of hospital admissions are drug-related. The costs for drug-related injuries that can be avoided are estimated at SEK 5.6–24.6 billion per year.
Dosell notifies the patient when it's time to take the medicine, and if the medicine is not taken despite the reminders, Dosell alerts healthcare professionals or relatives who can quickly prevent an injury and improve compliance, thus minimizing drug-related injuries.
Read more at www.dosell.se

About Us

10 Dosell are implemented in a new municipality.

Increased sales of the consumer version of Dosell

iZafe Group (publ.) hereby announces that the increased market investments have yielded good results. Already in the first week of TV advertising, the 50 Dosells the pharmacy had in stock on apoteket.se were sold.

Today, new Dosells were shipped Dosells from to Apoteket and they will continue to monitor warehouse figures daily, so that this problem does not arise again. The campaigns with TV advertising on several channels will last at least three months. In connection with this, several marketing activities will also take place.

“Medicinal robot is a completely new concept and Dosell is the first consumer version on the market. Wrong medication is a big problem in society, and we need to make everyone aware of how helpful Dosell actually is. We have received feedback from several customers who have started using Dosell that they cannot understand how it has been possible to be without a medicinal robot. Along with this, we will increase our campaign and launch a 30-day customer satisfaction guarantee. This guarantee means that you can return Dosell if you are not satisfied within 30 days and get your money back”. Says Anders Segerström, CEO of iZafe Group.

Link to the TV commercial: https://vimeo.com/684223960

About Us

Increased sales of the consumer version of Dosell

iZafe Group Q4 Interim Report, October-December 2021

iZafe Group AB (publ.) – today Febuary 18, releases its Q4 Interim Report.

Summary of financial performance

Net sales for the quarter amounted to SEK 220 (84) thousand. The quarter's sales consist of revenues attributable to the sale of the digital medication robot Dosell.
Operating profit for the quarter amounted to SEK -12,750 (-9,128) thousand.
Profit after financial items for the quarter amounted to -12 943 (-9 127) TSEK.
Cash flow for the period amounted to SEK 17,264 (-6,270) thousand. The positive cash flow for the comparison period is a result of the rights issue that has been carried out.
Earnings per share for the quarter before / after dilution amounted to SEK -0.2 (-0.3).
Equity per share at the end of the period amounted to SEK 0.6 (0.9).
The equity / assets ratio at the end of the period was 84.1 (84.0) percent.

Important events in the quarter

The first delivery of Dosell Consumer was sent to Apoteket AB on October 4 before the start of sales.
Deputy Chairman of the Board Göran Hermansson and CEO Anders Segerström together subscribe for an additional 458,000 units in the rights issue.
The final outcome of the rights issue of units, consisting of shares and warrants of series TO10 B has been announced. The rights issue has been subscribed for to a total of 100 per cent, where approximately 43.6 per cent were subscribed for with the support of unit rights, approximately 4.1 per cent were subscribed for without the support of unit rights and approximately 52.3 per cent were subscribed for by issue guarantors.
iZafe has filed several completions of its PCT patent application. In this way, the Company enabled a geographically broader patent protection, which is part of iZafe's strategy to strengthen and further develop its intangible assets internationally.
Launch of Dosell Consumer as an end product of the Italian healthcare service Sempli Farma began.
iZafe communicated that the price for the consumer version of Dosell is SEK 299 per month. This after the customer has bought the hardware for SEK 499 at apoteket.se
Commercial new launch of Dosell together with Hepro AS in Norway.
iZafe uses Mangold Fondkommission AB as a liquidity guarantor.
The first medical robots adapted for the Italian consumer market were sent to Sempli Farma in Italy for the pilot project.

Comments from the CEO

We have now raised enough capital to, for the first time ever, have enough liquidity to set a long-term and sustainable plan for the company. With all the new changes to the medication robot, we have now also got all of our partners to approve the new Dosell.

This has meant that during the fourth quarter we increased production significantly and produced at a higher rate than ever to meet market demand. We end the year with an increase in sales compared to the previous quarter, a clear indication that we have now started selling and that the market sees the value in our product. The difference from before is that we have done the preparatory work that was required, and we have thus created the conditions for us to now really enter an active sales phase.

We have now launched Europe's first consumer version of a medication robot. We have also been able to deliver the right medicine at the right time over 3,000 times to consumers in Sweden and have established ourselves in a country outside the Nordic region.

Our major marketing investment on the consumer side will begin at the end of February and the beginning of March with TV advertising in a number of channels and a number of other marketing activities and exciting collaborations. We are now working intensively to support our partners by increasing the sales rate and that everyone keeps a high focus on Dosell.

A sub-strategy so far has been to wait to enter new markets until existing partners are up and running and have fully approved our product. As this has now been achieved, we will shortly begin the work of prioritizing in a well-balanced way which new markets the company will begin to enter, with both existing partners and new ones. We already have several interesting tracks in new partners and markets, and we look forward to starting sales work there as well. Dosell is the basis of our strategy where we must ensure "the right medication at the right time" and with the help of this also be able to demonstrate the health effects in order to create a healthier, safer and more sustainable way for everyone to medicate.
In conclusion, it is positive to note that the pandemic is increasingly releasing its grip on society and business. For the company, this meant that more meetings could take place between colleagues, customers and partners during the quarter. We are now also working more proactively to have more digital meetings and digital e-training. I am enthusiastic about the progress we have made during the year and now we have initiated sales and marketing activities according to the plan we set. We still have a lot to do, and thanks to what we achieved in the last quarter of 2021, we now have the opportunity to accelerate significantly. We have now laid the basic conditions for becoming the obvious choice of digital aid to enable a healthier, safer and more independent life for the millions of people who multi-medicate in Sweden and the world.

About Us

IZafe Group Q4 2021 Kvartalsrapport (Eng)

New agreement regarding Dosell with the municipality of Scania.

iZafe Group (publ.) hereby announces that our partner Zafe Care Systems AB has signed an agreement with a municipality in western Scania.

The agreement starts with ten Dosell and implementation takes place at the time of writing. After that, it will be expanded with more Dosell gradually in the municipality, which has great potential.

"It is only now that our partners have been able to get started with the sale of Dosell, as the final approval of Dosell was delayed until the end of November. It is therefore gratifying that we can now in a short time see the second agreement come in from Zafe Care Systems AB ”. Says Tobias Johansson, VP, iZafe Group.

About Us

New agreement regarding Dosell with the municipality of Scania.

New agreement with municipality in Västmanland.

iZafe Group AB (publ.) – hereby announces that our partner Zafe Care Systems AB has signed an agreement with a municipality in Västmanland. The municipality will initially start with two medication robots to ensure processes and routines before several will be implemented successively.

“Since the turn of the year, Zafe Care Systems AB has had a dedicated resource that focuses full-time on the medication robot Dosell. It is an exciting period we have ahead of us and we are now slowly starting to see results, more agreements are to be expected.” says Per la Fleur, CEO, Zafe Care Systems AB

Zafe Care Systems AB, which was acquired by the AddLife Group, is part of Home Care, similar to Norwegian Hepro, and is one of the leading companies in welfare technology on the Swedish market. Their main customers are the state, municipalities and aid centers. Today, they work with more than 200 municipalities and are suitable thanks to their market-leading technology in all types of care homes.

About Us

New agreement with municipality in Västmanland.

iZafe Group invites shareholders and others to a Q&A session following the publishing of the fourth quarter report

iZafe Group AB (publ) – announces that in connection with the quarterly report for the fourth quarter of 2021, which will be published at 08:30 CET on February 18, 2022, shareholders, the media and other stakeholders will have the opportunity to ask questions to the company.

Questions will be answered by Chief Executive Officer Anders Segerström and published on Febuary 28, 2022 on iZafe Group's investor site under the heading Financial Reports, Investor Questions.

Please send your questions to before 10:00 (10 a.m.) CET on December 1, 2021.

About Us

iZafe Group invites shareholders and others to a Q&A session following the publishing of the fourth quarter report